- Home
- OCUL vs PHVS Comparison
OCUL vs PHVS Comparison
Compare OCUL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | PHVS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OCUL | PHVS |
|---|---|---|
| Price | $8.12 | $25.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | $22.90 | ★ $40.70 |
| AVG Volume (30 Days) | ★ 5.2M | 103.8K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,990,000.00 | N/A |
| Revenue This Year | $9.35 | N/A |
| Revenue Next Year | $92.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.23 | $11.51 |
| 52 Week High | $16.44 | $29.80 |
Technical Indicators
Market Signals| Indicator | OCUL | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 41.92 |
| Support Level | $6.23 | $24.25 |
| Resistance Level | $12.38 | $28.06 |
| Average True Range (ATR) | 0.44 | 1.17 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 10.86 | 12.71 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.